Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Department of Pharmacy, Pharmacology and Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22.
The Cardiff Acne Disability Index (CADI) is a questionnaire designed to measure the quality of life of teenagers and young adults with acne. It has been used clinically and within therapeutic research globally. This review aims to appraise all published data regarding the clinical and research experience of the CADI, its psychometric properties and validation, from its publication in 1992 until September 2020, in a single reference source. A literature search was conducted using MEDLINE via Ovid, PubMed, EBSCOhost, Web of Science and Scopus. All full articles in the English language were included. A total of 96 clinical studies were identified and analysed. The CADI has been used in 44 different countries, including four multinational studies, and has validated translations in 25 languages. Overall, 29 therapeutic interventions have used the CADI, demonstrating its responsiveness to change. The reliability of the CADI has been assessed in 14 studies through test-retest and internal consistency studies. In total, 57 studies have demonstrated aspects of its validity through correlation to other measures, and five studies have investigated the dimensionality of the CADI. There is evidence of high internal consistency, test-retest reliability, responsiveness to change and significant correlation with other objective measures. The minimal clinically important difference and validated score meaning bands have not yet been reported. This information is needed to improve the interpretability of CADI scores for clinical use and in research. The authors of the CADI have also rephrased Question 2 of the measure to ensure inclusivity.
卡迪夫痤疮残疾指数 (CADI) 是一种旨在衡量痤疮青少年和年轻人生活质量的问卷。它已在全球临床和治疗研究中使用。本综述旨在评估自 1992 年 CADI 发表以来,在单一参考来源中,关于 CADI 的临床和研究经验、心理测量特性和验证的所有已发表数据,包括其在全球 44 个不同国家的使用情况、25 种语言的验证翻译、44 项临床研究和 29 项治疗干预措施。该指数已在 44 个不同国家使用,包括四项多国研究,并已在 25 种语言中进行了验证翻译。总体而言,29 项治疗干预措施使用了 CADI,证明其对变化具有反应性。CADI 的可靠性已通过测试-重测和内部一致性研究在 14 项研究中进行了评估。总共有 57 项研究通过与其他措施的相关性证明了其有效性的各个方面,五项研究调查了 CADI 的维度。有证据表明其具有较高的内部一致性、测试-重测可靠性、对变化的反应性以及与其他客观措施的显著相关性。尚未报告最小临床重要差异和验证得分意义带。这些信息对于提高 CADI 分数在临床使用和研究中的可解释性很有必要。CADI 的作者还重新表述了该措施的问题 2,以确保包容性。